Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aurinia Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Aurinia Pharmaceuticals Inc.’s stock price such as:

• Aurinia Pharmaceuticals Inc.’s current stock price and volume
• Why Aurinia Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for AUPH from analysts
• AUPH’s stock price momentum as measured by its relative strength

About Aurinia Pharmaceuticals Inc. (AUPH)

Before we jump into Aurinia Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Want to learn more about Aurinia Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aurinia Pharmaceuticals Inc..

What Caused Aurinia Pharmaceuticals Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Aurinia Pharmaceuticals Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Aurinia Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aurinia Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Aurinia Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aurinia Pharmaceuticals Inc. (AUPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Aurinia Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Aurinia Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 5.63%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how Aurinia Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aurinia Pharmaceuticals Inc. Stock Price: Bottom Line

As of July 31, 2026, Aurinia Pharmaceuticals Inc.’s stock price is $14.880, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aurinia Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.